How TAKHZYRO works

Style
inner-content-contained, how-tak-works, section-no-bottom-margin, section-no-top-margin

How does targeting kallikrein stop the reaction that leads to HAE attacks?

As you may know, people with hereditary angioedema (HAE) don’t have enough C1-inhibitor protein, or the C1-inhibitor protein doesn’t work properly. This causes another protein, plasma kallikrein, to become overactive. This increase in kallikrein activity results in too much bradykinin, the substance that causes HAE attacks. TAKHZYRO decreases kallikrein activity.

Style
inner-content-contained, how-tak-works, section-no-bottom-margin, section-no-top-margin, section-no-top-padding

What should I know about TAKHZYRO and side effects?

The safety of TAKHZYRO was assessed in one of the longest prevention studies in HAE. See common side effects experienced by people in the study and ask your doctor any questions you have.

LEARN ABOUT POSSIBLE SIDE EFFECTS

Style
Inner-content-contained, background-lavender-light, icon-wings-lg, learn-more, section-no-top-margin, section-no-bottom-margin
https://main--takeda-eds-sites-takhzyro--onetakeda.hlx.page/fragments/isi
Style
Inner-content-contained, section-no-margin
id
Isi